CPI 203

Cat. No. 5331

CPI 203 C19H18ClN5OS [1446144-04-2]

Price and Availability

For CPI 203 pricing & availability please select your country from the drop down menu:
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: (6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide

Biological Activity

BET bromodomain inhibitor. Downregulates Myc expression, causes G1 cell cycle arrest and attenuates cell proliferation in human pancreatic neuroendocrine tumors. Arrests the growth of T cell acute lymphoblastic leukemia cells in vitro (EC50 = 91.2 nM). Also enhances the antitumor effect of rapamycin (Cat. No. 1292) in vitro and attenuates rapamycin induced Akt activation. Orally bioavailable.

Technical Data

Soluble to 100 mM in DMSO and to 10 mM in ethanol
>98 %
Store at -20°C

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet

Wong et al (2014) The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors. Cell Death Dis. 5 e1450. PMID: 25299775.

King et al (2013) The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 153 1552. PMID: 23791182.

If you know of a relevant reference for this product please let us know.

Citations are publications that use Tocris products.

Do you know of a great paper that uses CPI 203 from Tocris? If so please let us know.

View Related Products by Target

View Related Products by Product Action

Keywords: CPI 203, supplier, CPI203, BET, BRD4, domain, inhibitors, inhibits, (+)-JQ1, analogue, analog, 4499, Myc, G1, cell, cycle, arrest, antitumor, rapamycin, AKT, Tocris Bioscience, Bromodomain Inhibitor products

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Product Guide

Cancer Research Product Guide

Our Cancer Research Guide highlights over 750 products for cancer research. Request copy or view PDF today.

divider line

Epigenetics Toolbox

80 Epigenetic modulators supplied pre-dissolved in DMSO

Tocriscreen Epigenetics Toolbox

Includes many of the latest compounds available for epigenetics research. Covers a wide range of targets, such as bromodomains, KMTs, PRMTs and HDACs.

divider line

Epigenetics Review

Written by S. Müller-Knapp & P. Brown

Epigenetics Scientific Review

Our Epigenetics review gives an overview of the development of chemical probes for epigenetic targets, and discusses their biological effects. Request copy or view PDF today.

divider line

Epigenetics Research Bulletin

The epigenetics research bulletin gives an introduction into mechanisms of epigenetic regulation, and highlights key Tocris products for epigenetics targets. View PDF today.

divider line

New Products in this Area


Potent and selective inhibitor of cat eye syndrome chromosome region, candidate 2 (CECR2)

NI 42

High affinity BRPF inhibitor

BI 9564

Potent and selective BRD9 and BRD7 inhibitor; orally active


Dual BRD4 and CBP/p300 bromodomain inhibitor


Negative control for PF-CBP1 (Cat. No. 5801)

Sign-up for new product e-alerts
divider line

LinkedIn Updates

Follow Tocris on LinkedIn

Follow us on LinkedIn!

Visit our LinkedIn page for the latest Tocris news, events and updates.